Thompson Siegel & Walmsley LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 14,345 shares of the medical instruments supplier’s stock, valued at approximately $2,784,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the period. Oppenheimer Asset Management Inc. raised its position in Becton, Dickinson and Company by 71.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after purchasing an additional 34,437 shares in the last quarter. Assetmark Inc. raised its position in Becton, Dickinson and Company by 49.5% during the third quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after purchasing an additional 74,795 shares in the last quarter. Vanguard Group Inc. raised its position in Becton, Dickinson and Company by 0.5% during the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after purchasing an additional 147,041 shares in the last quarter. Finally, Skba Capital Management LLC raised its position in Becton, Dickinson and Company by 1,619.9% during the third quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock valued at $10,765,000 after purchasing an additional 54,170 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on BDX shares. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. The Goldman Sachs Group decreased their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. JPMorgan Chase & Co. decreased their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Finally, Stifel Nicolaus decreased their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $183.64.
Becton, Dickinson and Company Price Performance
BDX stock opened at $144.07 on Wednesday. The company has a 50 day simple moving average of $151.40 and a 200 day simple moving average of $176.68. The stock has a market cap of $39.70 billion, a price-to-earnings ratio of 36.47, a P/E/G ratio of 10.29 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
